Oncobiotix was founded by the scientists who discovered the biology, and is led by an operator with a track record of getting new cancer immunotherapies into patients — including a NASDAQ IPO and a company acquisition.
Has taken three different kinds of cancer immunotherapy from lab to clinic — cancer vaccines, tumor-killing viruses, and T-cell therapies. Founder of Jennerex Therapeutics (acquired), and founder and SVP of Turnstone Biologics (NASDAQ IPO).
More than two decades in cancer immunotherapy, with a proven laboratory-to-clinic track record. Director of the Riddell Centre for Cancer Immunotherapy at the University of Calgary.
Over a decade of work where the microbiome meets cancer immunotherapy, and the lead inventor of OBX34. Winner of the Alberta Cancer Foundation Breakthrough Fund.
Oncobiotix's science emerged from academic cancer-immunology research — pairing deep microbiome-immunology insight with a team that has repeatedly translated discovery into clinical programs.
The next decade of cancer immunotherapy won't only be won by new drugs — but by getting the ones we already have to work for the patients they fail today.
Partners across the cancer-immunotherapy world.